Methods and reagents for analyzing protein-protein interfaces
US-10948495-B2 · Mar 16, 2021 · US
Ras inhibitors
US12280113B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12280113-B2 |
| Application number | US-202318188966-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2023 |
| Priority date | Sep 15, 2020 |
| Publication date | Apr 22, 2025 |
| Grant date | Apr 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the following structure: or a pharmaceutically acceptable salt thereof. 2. A compound of the following structure: 3. A pharmaceutical composition comprising a compound of the following structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 4. A pharmaceutical composition comprising a compound of the following structure: and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
containing three or more hetero rings · CPC title
Antineoplastic agents · CPC title
in which the condensed systems contains four or more hetero rings · CPC title
in which the condensed system contains four or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12280113B2 cover?
- The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
- Who is the assignee on this patent?
- Revolution Medicines Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).